CRISPR Therapeutics AG (NASDAQ:CRSP) shares jumped on Thursday, building on its Feb. 13 earnings report that showed growing momentum for its lead gene therapy and a deepening pipeline.



<h2>Casgevy Revenue </h2>



Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in the fourth quarter and $116 million for the full-year 2025. A total of 64 patients received infusions in the fourth quarter alone, with 147 initiating treatment through the first cell collection for the year — nearly triple 2024 levels.



William Blair analyst Sami Corwin noted that “the increase to 147 first cell collections strengthens confidence that higher initiation volumes will translate into materially greater revenue in 2026.”



Beyond hematology, the company continues to advance its in vivo liver editing programs.



<h2>Short Interest</h2>



Short interest rose from 21.89 million to 22.64 million shares, representing 26.45% of the float. At an average daily volume of 1.71 million shares, shorts would need roughly 13 days to cover.



<h2>Technical Analysis</h2>



CRSP is trading 14.4% above its 20-day SMA and 3.0% above its 100-day SMA, showing strong short-term extension while still holding a constructive intermediate trend.



Shares are up 33.31% over the past 12 months and are currently positioned closer to their 52-week highs than lows.



<ul>
<li>Key Resistance: $61.00</li>



<li>Key Support: $52.00</li>
</ul>



<h2>Earnings &amp; Analyst Outlook</h2>



Looking further out, the next major catalyst for the stock arrives with the May 5, earnings report.



<ul>
<li>EPS Estimate: $-1.19 (Up from $-1.58 YoY)</li>



<li>Revenue Estimate: $6.13 million (Up from 86 cents million YoY)</li>
</ul>



Analyst Consensus &amp; Recent Actions: The stock carries a Buy Rating with an average price target of $72.24. Recent analyst moves include:



<ul>
<li>Chardan Capital: Buy (Raises Target to $76.00) (Feb. 17)</li>



<li>TD Cowen: Hold (Raises Target to $45.00) (Feb. 13)</li>



<li>Evercore ISI Group: Outperform (Raises Target to $74.00) (Feb. 13)</li>
</ul>



CRSP Price Action: CRISPR Therapeutics shares were up 6.30% at $58.68 at the time of publication on Thursday, according to Benzinga Pro data.



Photo by T. Schneider via Shutterstock

IDNA

WDNA

CRISPR Therapeutics (NASDAQ:CRSP) shares surged on Thursday following a positive earnings report, highlighting a strong pipeline for gene therapy. Revenue from Casgevy, the gene-editing therapy, reached $54 million in Q4 2025, with 64 patients treated. Analyst Sami Corwin expressed confidence in increased initiation volumes translating to higher revenue in 2026. The stock is currently trading 14.4% above its 20-day SMA and has a Buy rating with an average price target of $72.24. Shares rose 6.30% to $58.68 at publication.

Why Is CRISPR Therapeutics Stock Surging Thursday?